Free Trial
NASDAQ:ATHA

Athira Pharma (ATHA) Stock Price, News & Analysis

Athira Pharma logo
$0.38 +0.01 (+2.38%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Athira Pharma Stock (NASDAQ:ATHA)

Key Stats

Today's Range
$0.37
$0.40
50-Day Range
$0.28
$0.49
52-Week Range
$0.22
$3.67
Volume
58,098 shs
Average Volume
370,600 shs
Market Capitalization
$14.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.25
Consensus Rating
Hold

Company Overview

Athira Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

ATHA MarketRank™: 

Athira Pharma scored higher than 61% of companies evaluated by MarketBeat, and ranked 338th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Athira Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Athira Pharma has received no research coverage in the past 90 days.

  • Read more about Athira Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Athira Pharma are expected to grow in the coming year, from ($2.35) to ($0.82) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Athira Pharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Athira Pharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Athira Pharma has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Athira Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    3.08% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 21.97%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Athira Pharma does not currently pay a dividend.

  • Dividend Growth

    Athira Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.08% of the float of Athira Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Athira Pharma has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Athira Pharma has recently decreased by 21.97%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Athira Pharma this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for ATHA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Athira Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,743.00 in company stock.

  • Percentage Held by Insiders

    19.80% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Athira Pharma's insider trading history.
Receive ATHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter.

ATHA Stock News Headlines

Athira Pharma (ATHA) to Release Quarterly Earnings on Thursday
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
See More Headlines

ATHA Stock Analysis - Frequently Asked Questions

Athira Pharma's stock was trading at $0.5867 at the start of the year. Since then, ATHA stock has decreased by 34.4% and is now trading at $0.3850.

Athira Pharma, Inc. (NASDAQ:ATHA) released its quarterly earnings results on Friday, May, 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.03.

Athira Pharma (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel served as the underwriters for the IPO and JMP Securities was co-manager.

Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META).

Company Calendar

Last Earnings
5/09/2025
Today
8/04/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATHA
CIK
1620463
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$22.00
Low Price Target
$0.50
Potential Upside/Downside
+2,822.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$96.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-142.99%
Return on Assets
-106.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.26
Quick Ratio
7.26

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.16 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
39,040,000
Free Float
31,312,000
Market Cap
$15.03 million
Optionable
Optionable
Beta
3.00

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:ATHA) was last updated on 8/4/2025 by MarketBeat.com Staff
From Our Partners